DDInter1294 DDInter1595
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin that stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Nilutamide {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Rilpivirine
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Nilutamide {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Nilutamide {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Nilutamide {u} (Compound) causes {v} (Side Effect) Depression
Depression {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rilpivirine
Nilutamide {u} (Compound) resembles {v} (Compound) Flutamide
Flutamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Nilutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Enzalutamide {u} may lead to a major life threatening interaction when taken with {v} Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Nilutamide {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Zafirlukast
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Nilutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rilpivirine (Compound)
Nilutamide (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound)
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Rilpivirine
Nilutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Etravirine (Compound) and Etravirine (Compound) resembles Rilpivirine (Compound)
Nilutamide (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Nilutamide (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Etravirine (Compound) and Etravirine (Compound) resembles Rilpivirine (Compound)
Nilutamide (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Nilutamide (Compound) resembles Flutamide (Compound) and Flutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Nilutamide (Compound) resembles Enzalutamide (Compound) and Enzalutamide may lead to a major life threatening interaction when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Nilutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Zafirlukast (Compound) and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine